NXS logo

Next Science Limited Stock Price

ASX:NXS Community·AU$43.9m Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Create a narrative

NXS Share Price Performance

AU$0.15
-0.05 (-25.00%)
44.3% undervalued intrinsic discount
AU$0.27
Fair Value
AU$0.15
-0.05 (-25.00%)
44.4% undervalued intrinsic discount
AU$0.27
Fair Value
Price AU$0.15
AnalystConsensusTarget AU$0.27

NXS Community Narratives

AnalystConsensusTarget·
Fair Value AU$0.27 44.3% undervalued intrinsic discount

FDA Engagement And XPERIENCE Will Secure Future Confidence

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

Recent NXS News & Updates

Even With A 125% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely

Jul 17
Even With A 125% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely

Next Science Limited (ASX:NXS) Might Not Be As Mispriced As It Looks After Plunging 29%

May 28
Next Science Limited (ASX:NXS) Might Not Be As Mispriced As It Looks After Plunging 29%
User avatar

Cost Restructuring And XPERIENCE Trials Will Strengthen Future Position

Transitioning to a variable cost structure decreased cash burn, likely improving net margins and EBITDA as growth continues.

Would Next Science (ASX:NXS) Be Better Off With Less Debt?

Mar 17
Would Next Science (ASX:NXS) Be Better Off With Less Debt?

Even With A 26% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely

Jan 22
Even With A 26% Surge, Cautious Investors Are Not Rewarding Next Science Limited's (ASX:NXS) Performance Completely

Next Science Limited Key Details

US$22.1m

Revenue

US$3.9m

Cost of Revenue

US$18.2m

Gross Profit

US$27.6m

Other Expenses

-US$9.4m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.032
Gross Margin
82.48%
Net Profit Margin
-42.74%
Debt/Equity Ratio
-849.6%

Next Science Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Slight risk and slightly overvalued.

4 Risks
0 Rewards
View Full Analysis

About NXS

Founded
2012
Employees
n/a
CEO
Harry Hall
WebsiteView website
www.nextscience.com

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Market Insight

Header cover image

✨Rare Earths: Tiny Market, Outsized Influence

Richard Bowman avatarRichard Bowman
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Last Week
⚡ Utilities: Defensive Dividends Meet the AI Power Surge

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

Australian Market Performance

  • 7 Days: 1.3%
  • 3 Months: 5.7%
  • 1 Year: 9.4%
  • Year to Date: 9.4%
The market has climbed 1.3% in the last 7 days, lead by the Materials sector with a gain of 2.9%. As for the past 12 months, the market is up 9.4%. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›